In the early phase 2 result, selumetinib was effective in treating children with recurrent/refractory low-grade glioma (LGG), including those with neurofibromatosis type 1 (NF-1)-associated LGG and pilocytic astrocytomas (PA) harboring BRAF V600E mutation or BRAF-KIAA 1549 fusion. The gene discussed is BRAF; the disease is low grade glioma.